Despite the fact that Edwards LifeSciences 1st generation GlucoClear® received CE-Mark in Europe in October 2009 for in-hospital critical use, they are still conducting marketing trials in Europe to gather data and neither company expects significant revenue from the 1st generation GlucoClear®. In fact, Edwards LifeSciences CEO Mike Mussallem stated “…we're really concentrating on working out the kinks and getting this technology understood” during last month’s conference call and admitted that a 2nd generation system will be required to be successful. However, DexCom did state they are working on a 5th generation sensor platform which applies aspects of their blood-based hospital sensor, for Edwards LifeSciences, into a subcutaneous sensor for both a future ambulatory sensor and a subcutaneous sensor for use in the hospital outside of critical care.
Echo Therapeutics Symphony™ transdermal continuous glucose monitor (tCGM) system is a unique needle-free, wireless system and set to begin a pivotal clinical trial in ICU/Critical Care patients in Q2’10. We believe this puts Echo Therapeutics ahead of the curve with respect to tougher FDA standards for hospital use. We calculate that the U.S. market for diabetic and pre-diabetic patients in ICU, is approximately $400 million.
At 1/10th the market cap and pivotal trials set to begin, ECTE seems to be the better play in this space at the moment.